TIM XIAO, CFA, FRM
Tim Xiao, CFA, FRM, is a Principal at Delos Capital since its inception in 2014 and has over 13 years’ experience in investment banking and life sciences investment. Tim started his career as an investment banker at China International Capital and later joined the Investment Banking Division of Goldman Sachs where he completed a series of industry-defining transactions with a total deal value of over US$4 billion.
Tim serves as a Board member for Eccogene, Clover Biopharmaceuticals, OncoMyx Therapeutics, Curatia Medical, STRM.Bio, and as a Board Observer for Allecra Therapeutics and Intrinsic Therapeutics. Tim was previously a Board member for Luqa Pharmaceuticals (acquired by China Medical System HKEx: 867).
Tim holds a Bachelor’s degree in International Business from Shanghai Jiao Tong University and is a CFA charterholder.